Healthcare -
Medical - Instruments & Supplies - NASDAQ - US
$ 4.66
1.08 %
$ 254 K
Market Cap
None
P/E
1. INTRINSIC VALUE
2. FUNDAMENTAL
ANALYSIS
Price Chart STSS
FINANCIALS
Balance Sheet
Sharps Technology, Inc.
| Current Assets | 3.17 M |
| Cash & Short-Term Investments | 864 K |
| Receivables | 102 K |
| Other Current Assets | 2.21 M |
| Non-Current Assets | 4.14 M |
| Long-Term Investments | 0 |
| PP&E | 4.04 M |
| Other Non-Current Assets | 105 K |
| Current Liabilities | 5.19 M |
| Accounts Payable | 977 K |
| Short-Term Debt | 3.76 M |
| Other Current Liabilities | 445 K |
| Non-Current Liabilities | 132 K |
| Long-Term Debt | 0 |
| Other Non-Current Liabilities | 132 K |
EFFICIENCY
Earnings Waterfall
Sharps Technology, Inc.
| Revenue | 0 |
| Cost Of Revenue | 0 |
| Gross Profit | 0 |
| Operating Expenses | 9.63 M |
| Operating Income | -9.63 M |
| Other Expenses | -331 K |
| Net Income | -9.3 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Sharps Technology, Inc.
| Net Income | -9.3 M |
| Depreciation & Amortization | 774 K |
| Capital Expenditures | -139 K |
| Stock-Based Compensation | 521 K |
| Change in Working Capital | 0 |
| Others | 1.1 M |
| Free Cash Flow | -7.07 M |
Wall Street Analysts Price Targets
Sharps Technology, Inc.
STSS has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
STSS does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Sharps Technology, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
10.8 K USD 1
0-3 MONTHS
20.1 K USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Sharps Technology, Inc. Reminds Shareholders to Vote Before Important Shareholder Meeting on March 28, 2025
NEW YORK, March 20, 2025 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (Nasdaq: STSS) (the “Company” or “Sharps”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, is reminding shareholders to vote their proxy in favor of the Company's proposal before the shareholder meeting, which is scheduled to be held on March 28, 2025, at 10:00 a.m. Eastern Time.
globenewswire.com
- 2 months ago
Sharps Technology's CEO Issues Corporate Update Highlighting Agreements for SecureGard and SoloGard and Revenue Developments from Manufacturing Operations in Hungary
Company is strategically positioned following the recent $20 million capital raise, enhancing manufacturing capabilities to accelerate qualification and shipments under existing agreements Company is strategically positioned following the recent $20 million capital raise, enhancing manufacturing capabilities to accelerate qualification and shipments under existing agreements
globenewswire.com
- 2 months ago
Sharps Technology, Inc. Announces Closing of Upsized $20.0 Million Underwritten Public Offering
NEW YORK, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (NASDAQ: STSS) (the “Company”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, today announced the closing of its previously announced firm commitment underwritten public offering. Gross proceeds to the Company were approximately $20.0 million, before deducting underwriting fees and other offering expenses payable by the Company. The offering closed on January 29, 2025.
globenewswire.com
- 3 months ago
Sharps Technology's CEO Issues Shareholder Letter Highlighting Hungary Manufacturing Facility Expansion Plans to Increase SecureGard and SoloGard Product Supply and Revenue
NEW YORK, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc., (NASDAQ: “STSS” and “STSSW”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, issues a shareholder letter from Robert Hayes, the Company's Chief Executive Officer.
globenewswire.com
- 5 months ago
Sharps Regains Nasdaq Listing Compliance
NEW YORK, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (NASDAQ: “STSS” and “STSSW”) (“Sharps”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, today announced that on November 13, 2024, the Company was notified by the Nasdaq Stock Market (“Nasdaq”) that the Company had regained compliance with the minimum bid price requirement of $1.00 per share for continued listing on the Nasdaq Stock Market, as set forth in Nasdaq Listing Rule 5550(a)(2) as of November 5, 2024.
globenewswire.com
- 6 months ago
Sharps Technology, Inc. Announces Stockholders' Approval of Reverse Stock Split Ratio and Effective Date
NEW YORK, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (NASDAQ: “STSS” and “STSSW”) ("Sharps"), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, today announced that it will effect a one-for-22 reverse stock split (the "reverse split") of its common stock, par value $0.0001 per share (the "Common Stock"), that will become effective on October 15, 2024 at 11:59 PM Eastern Time, before the opening of trading on The Nasdaq Capital Market ("Nasdaq"). Sharps has requested that its Common Stock begin trading on October 16, 2024, on a post-reverse split basis on the Nasdaq under the existing symbol "STSS".
globenewswire.com
- 7 months ago
Sharps Technology, Inc. Reminds Shareholders to Vote Before Important Shareholder Meeting on October 7, 2024
NEW YORK, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (NASDAQ: STSS) (the “Company”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, is reminding shareholders to vote their proxy in favor of the Company's proposal before the shareholder meeting scheduled to be held on October 7, 2024 at 10:00 a.m. Eastern Time.
globenewswire.com
- 7 months ago
Aegis Capital Corp. Acted as Exclusive Placement Agent on a $3.5 Million Bridge Financing for Sharps Technology, Inc. (NASDAQ:STSS)
NEW YORK, NY / ACCESSWIRE / September 27, 2024 / Aegis Capital Corp. acted as Exclusive Placement Agent on a $3.5 Million Bridge Financing for Sharps Technology, Inc. (NASDAQ:STSS). About Sharps Technology, Inc. Sharps Technology, Inc., a medical device company, engages in the design, research and development, manufacturing, and commercialization of safety syringe products in the United States.
accesswire.com
- 7 months ago
Sharps Technology, Inc. Closes $3.5 Million Bridge Financing
NEW YORK, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (NASDAQ: STSS) (the “Company”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, today announced the closing of its previously announced secured bridge loan financing (the “Bridge Financing”) of approximately $3.5 million.
globenewswire.com
- 7 months ago
Sharps Technology, Inc. Announces $3.5 Million Bridge Financing
NEW YORK, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (NASDAQ: STSS) (the “Company”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, today announced that it has entered into definitive agreements with institutional investors for a secured bridge loan financing (the “Bridge Financing”) of approximately $3.5 million.
globenewswire.com
- 7 months ago
Sharps Technology Announces Continued Listing on Nasdaq Pending Results of an Upcoming Special Shareholders' Meeting
NEW YORK, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc., (NASDAQ: STSS and STSSW) (“Sharps Technology” or the “Company”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, announced today that the Company has secured approval from The Nasdaq Stock Market (“Nasdaq” or the “Exchange”) to maintain its listing, subject to conditions outlined below.
globenewswire.com
- 8 months ago
Sharps Technology CEO Urges Shareholders to Vote in Support of the Three Proposals by the July 12 Voting Deadline
Robert Hayes issues a letter to shareholders asking their voting approval on three proposals vital to the Company's continued growth.
globenewswire.com
- 10 months ago
8. Profile
Summary
Sharps Technology, Inc. STSS
COUNTRY
US
INDUSTRY
Medical - Instruments & Supplies
MARKET CAP
$ 254 K
Dividend Yield
0.00%
Description
Sharps Technology Inc., a medical device company, researches, designs, develops, manufactures, distributes, and sells safety syringe products in the United States. It offers Sharps Provensa, an ultra-low waste space syringe for the administration of various vaccines and injectable medications. The company was incorporated in 2017 and is based in Melville, New York.
Contact
105 Maxess Road, Melville, NY, 11747
https://sharpstechnology.com
IPO
Date
April 14, 2022
Employees
55
Officers
Mr. Frank Parrado
Corporate Controller
Mr. Andrew R. Crescenzo CPA
Chief Financial Officer
Mr. Robert M. Hayes
Chief Executive Officer & Director
Mr. Ben Scheu
Senior Director of Sales